



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1978 45 Y

Referral Testing

Collected: 08/31/2023 09:17 Received: 08/31/2023 09:17

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: Anti-Hu (antineuronal nuclear antibody, type1), See Note, QCRL

POSITIVE
This test detected abnormal levels of anti-Hu antibodies.

Technical Results See Note QCRL

Interpretive Result Table

INTERPRETIVE RESULT: Positive
TEST: anti-Hu
TECHNICAL RESULT: 1:1,600
REFERENCE RANGE: Serum <1:100

Methods See Note QCRL

Detection of antibodies was performed by automated nanoliter scale immunoassay.

Although rare, false positive or false negative results may occur. All results should be interpreted in the context of clinical findings, relevant history, and other laboratory data.

Comments See Note QCRL

Comments: Positive test results are associated with a diagnosis of an autoimmune etiology for the neurological symptoms associated with paraneoplastic disorder.

Recommendations: Health care providers, please contact the Athena Diagnostics Client Services Department at 1-800-394-4493 if you wish to speak with a clinical consultant regarding this test result.

Background information: Paraneoplastic neurological syndromes or disorders (PNS or PND) are rare immune-mediated disorders resulting from nervous system damage due to the remote effects of a tumor. PND of the central nervous system may occur in association with either onconeural antibodies directed against intracellular antigens, or antibodies targeted against neuronal surface antigens. These autoantibodies have been associated with various clinical

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1978 45 Y

Referral Testing

Collected: 08/31/2023 09:17 Received: 08/31/2023 09:17

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: presentations and malignancies. Row 2: References, See Note, QCRL

- 1. Titulaer, MJ, et al. (2011) Eur J Neurol 18: 19-e3. (PMID: 20880069)
2. Zuliani, L, et al. (2012) J Neurol Neurosurg Psychiatry 83: 638-45. (PMID: 22448032)

This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Laboratory oversight provided by Vivekananda Datta, M.D., Ph.D., CLIA license holder, Athena Diagnostics (CLIA# 22D0069726)

Testing performed at:
Athena Diagnostics 200 Forest Street Marlborough, MA 01752

Test Performed at:
Athena Diagnostics, Inc.
200 Forest Street, 2nd Floor
Marlborough, MA 01752 V Datta MD, PhD

Performing Site:
QCRL: QUEST DIAGNOSTICS REFERENCE LAB CAPISTRANO 33608 Ortega Highway San Juan Capistrano CA 92675

Reported Date: 2023.08.31 9:22 HU

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED